Compare Citius Pharmaceuticals Inc (CTXR) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Orion Office REIT Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.68 (market cap $20.01M), while Orion Office REIT Inc trades at $2.75 (market cap $158.01M). The key difference: Orion Office REIT Inc is far larger — about 7.9× Citius Pharmaceuticals Inc's market cap, and Orion Office REIT Inc pays a 2.89% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | ONL | |
|---|---|---|
Market Cap | $20.01M | $158.01M |
Sector | Health | Real Estate |
52-Week High | $1.82 | $3.04 |
52-Week Low | $0.48 | $1.93 |
Enterprise Value | $16.23M | $574.95M |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
ONL trades at $2.80, up 1.82% with a bullish technical signal. The company reported mixed Q2 2026 results with an EPS beat but faces fundamental challenges including declining revenue and negative net income margins. Analyst consensus is split 50/50 between Buy and Hold ratings. Recent news highlights strategic review progress and portfolio repositioning efforts.
Outlook remains cautious due to persistent losses and revenue decline, though low P/B ratio and dividend payments offer some value. Key risks include continued negative profitability and high debt levels. The stock presents speculative value for investors tolerant of turnaround execution risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
